TACE combined with sorafenib for inoperable hepatocellular carcinoma:analysis of treatment interval / 介入放射学杂志
Journal of Interventional Radiology
;
(12): 769-771, 2014.
Artículo
en Chino
| WPRIM
| ID: wpr-454517
ABSTRACT
Objective To investigate the clinical efficacy of transarterial chemoembolization (TACE) combined with sorafenib for the treatment of inoperable hepatocellular carcinoma (HCC), and to discuss the influence of treatment interval on the survival time. Methods During the period from July 2008 to May 2011 at authors’ hospital, a total of 50 patients with inoperable HCC were treated with TACE together with sorafenib. The treatment intervals between each TACE procedure were recorded. The results were analyzed. Results Up to Dec. 31, 2011, the median follow-up time of the 50 patients was 310 days. The mean interval between TACE treatments was 69 days before the combination treatment was employed , while the mean interval was 112 days after the combination treatment started , and the longest interval was 648 days. Conclusion Combination treatment TACE with sorafenib can remarkably prolong the treatment interval in patients with inoperable HCC, thus the patient can get more survival benefits.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Journal of Interventional Radiology
Año:
2014
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS